Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
fMRI of Intravenous Ketamine for Treatment Resistant Bipolar Depression
NCT06620042Phase 2Completed
- Start
- Nov 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in bipolar disorder (BD). Primary endpoint: Acute Response Changes in Subgenual Cingulate Functional Connectivity at 3 weeks. Started Nov 2024; status: completed.
02
Drugs
ketamine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT06620042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620042.